Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 55 Continued single digit volume growth within the insulin segments globally Fast-acting insulin Segment volume Premix insulin Long-acting insulin Segment volume TresibaⓇ share - LevemirⓇ share NovoRapidⓇ market share Segment volume NovoMixⓇ market share tMU 200 CAGR¹ volume: 5.3% MI penetration: 78.1% 100% tMU 200 CAGR¹ volume: 1.5% MI penetration: 45.5% 100% tMU 200 CAGR¹ volume: 6.2% MI penetration²: 83.5% 100% 80% 80% 80% 160 160 150 +60% 60% 60% 120 120 100 +40% 40% 40% 80 80 40 + 20% 40 20% 50 20% 0% 0% 0% Aug 2013 Aug 2018 Aug 2013 Aug 2018 Aug Aug 2013 2018 1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units Note: Modern insulin (MI) penetration is of total segment, i.e. including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology Source: IQVIA MAT Aug, 2018 volume figures changing diabetes novo nordisk

View entire presentation